Bruce B. Feinberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Bruce B. Feinberg has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Deborah J. Anderson
Departments of Obstetrics, Gynecology and Reproductive Biology and
1 shared publicationRichard M. Jack
Rheumatology and Immunology, Brigham and Women's Hospital, Boston, MA
1 shared publication- Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
1 shared publication
Latest Publications
- 19 January 2006
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 55 (2) , 84-98
Preeclampsia: the Death of Goliath
In this review, a novel and unifying pathophysiologic mechanism of preeclampsia is presented whereby a minimal excess of placental immune complex production versus removal causes a proinflammatory autoamplification cascade of trophoblast apoptosis/necrosis and oxidative stress, culminating in clinical preeclampsia. This concept immediately leads to a plethora of new and robust therapeutic strategies.
- 19 January 2006
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 55 (2) , 84-98
Preeclampsia: the Death of Goliath
In this review, a novel and unifying pathophysiologic mechanism of preeclampsia is presented whereby a minimal excess of placental immune complex production versus removal causes a proinflammatory autoamplification cascade of trophoblast apoptosis/necrosis and oxidative stress, culminating in clinical preeclampsia. This concept immediately leads to a plethora of new and robust therapeutic strategies.
- 18 November 2005
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 54 (6) , 352-357
Low Erythrocyte Complement Receptor Type 1 (CR1, CD35) Expression in Preeclamptic Gestations
Problem: Erythrocyte complement receptor type 1 (E‐CR1) is the main immune complex clearance mechanism in humans. Decreased E‐CR1 expression is noted in certain inflammatory disorders. Recent evidence implicates inflammation in the pathogenesis of preeclampsia. We investigated whether E‐CR1 is decreased in preeclampsia.Method of study: E‐CR1 protein expression was quantified by radioimmunoassay. Plasma concentration of soluble CR1 was quantified using a specific enzyme linked immunosorbent assay. Quantitative genotypes were evaluated by HindIII restriction fragment length polymorphism analysis.Results: E‐CR1 expression was reduced in patients with preeclampsia. Lack of neoantigen expression (indicative of enzymatic cleavage of CR1) or elevated plasma‐soluble CR1 was evidence against an acquired loss of E‐CR1. Genotype analysis revealed a higher frequency of a CR1 allele associated with low E‐CR1 expression in preeclampsia when compared with normal pregnant controls.Conclusions: E‐CR1 expression is decreased in preeclamptic patients and levels correlate with severity of disease. This condition may have a genetic basis in some patients.
- 18 November 2005
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 54 (6) , 352-357
Low Erythrocyte Complement Receptor Type 1 (CR1, CD35) Expression in Preeclamptic Gestations
Problem: Erythrocyte complement receptor type 1 (E‐CR1) is the main immune complex clearance mechanism in humans. Decreased E‐CR1 expression is noted in certain inflammatory disorders. Recent evidence implicates inflammation in the pathogenesis of preeclampsia. We investigated whether E‐CR1 is decreased in preeclampsia.Method of study: E‐CR1 protein expression was quantified by radioimmunoassay. Plasma concentration of soluble CR1 was quantified using a specific enzyme linked immunosorbent assay. Quantitative genotypes were evaluated by HindIII restriction fragment length polymorphism analysis.Results: E‐CR1 expression was reduced in patients with preeclampsia. Lack of neoantigen expression (indicative of enzymatic cleavage of CR1) or elevated plasma‐soluble CR1 was evidence against an acquired loss of E‐CR1. Genotype analysis revealed a higher frequency of a CR1 allele associated with low E‐CR1 expression in preeclampsia when compared with normal pregnant controls.Conclusions: E‐CR1 expression is decreased in preeclamptic patients and levels correlate with severity of disease. This condition may have a genetic basis in some patients.